Effect of cinacalcet availability and formulary listing on parathyroidectomy rate trends

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Lafrance, Jean Philippe ^a,b,c   Cardinal, Héloïse ^b,d   Leblanc, Martine ^b,c   Madore, François ^b,e   Pichette, Vincent ^a,b,c   Roy, Louise ^b,d   Le Lorier, Jacques ^b,d  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Calcimimetic agents; Epidemiologic studies; Hyperparathyroidism, Secondary; Parathyroidectomy; Renal dialysis

Indexed keywords

CINACALCET;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG FORMULARY; DRUG MARKETING; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PARATHYROIDECTOMY; PERITONEAL DIALYSIS; PREVALENCE; REIMBURSEMENT; SEX RATIO; TREND STUDY;

AGED; CHEMISTRY, PHARMACEUTICAL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROIDECTOMY; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 84876954443     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-100     Document Type: Article

References (22)

1. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009 113 1 S130 19644521
2. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG, N Engl J Med 2004 350 15 1516 1525 10.1056/NEJMoa031633 15071126 (Pubitemid 38477776)
3. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM, Kidney Int 2005 68 4 1793 1800 10.1111/j.1523-1755.2005.00596.x 16164656 (Pubitemid 43169924)
4. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. The EVOLVE Trial Investigators, N Engl J Med 2012 367 2482 2494 23121374
5. Trends in parathyroidectomy rates in US hemodialysis patients from 1992 to 2007. Li S, Chen YW, Peng Y, Foley RN, St Peter WL, Am J Kidney Dis 2011 57 4 602 611 10.1053/j.ajkd.2010.10.041 21186072
6. The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002. Foley RN, Li S, Liu J, Gilbertson DT, Chen SC, Collins AJ, J Am Soc Nephrol 2005 16 1 210 218 15563573 (Pubitemid 43073175)
7. Parathyroidectomy rates among United States dialysis patients: 1990-1999. Kestenbaum B, Seliger SL, Gillen DL, Wasse H, Young B, Sherrard DJ, Weiss NS, Stehman-Breen CO, Kidney Int 2004 65 1 282 288 10.1111/j.1523-1755.2004.00368.x 14675061 (Pubitemid 38037515)
8. Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study. Malberti F, Marcelli D, Conte F, Limido A, Spotti D, Locatelli F, J Am Soc Nephrol 2001 12 6 1242 1248 11373348 (Pubitemid 32472638)
9. Rates of transcervical and pertrochanteric hip fractures in the province of Quebec, Canada, 1981-1992. Levy AR, Mayo NE, Grimard G, Am J Epidemiol 1995 142 4 428 436 7625408
10. Changing rates of stroke in the province of Quebec, Canada: 1981-1988. Mayo NE, Goldberg MS, Levy AR, Danys I, Korner-Bitensky N, Stroke 1991 22 5 590 595 10.1161/01.STR.22.5.590 2028487
11. Discordance of databases designed for claims payment versus clinical information systems. Implications for outcomes research. Jollis JG, Ancukiewicz M, DeLong ER, Pryor DB, Muhlbaier LH, Mark DB, Ann Intern Med 1993 119 8 844 850 10.7326/0003-4819-119-8-199310150-00011 8018127 (Pubitemid 24012651)
12. Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment. Tamblyn R, Reid T, Mayo N, McLeod P, Churchill-Smith M, J Clin Epidemiol 2000 53 2 183 194 10.1016/S0895-4356(99)00136-5 10729691 (Pubitemid 30151224)
13. Hipel KW, McLeod AI, Time Series Modelling of Water Resources and Environmental Systems Amsterdam: Elsevier Scientific Publishing Company 1994
14. Intervention Analysis with Applications to Economic and Environmental Problems. Box GE, Tiao GC, J Am Stat Assoc 1975 70 349 70 79 10.1080/01621459.1975.10480264
15. U.S. Renal Data System, USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2011
16. Canadian Institute for Health Information, Treatment of End-Stage Organ Failure in Canada, 2000 to 2009 (2011 Annual Report) Ottawa: CIHI 2011
17. Clinical epidemiology of parathyroidectomy in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Slinin Y, Foley RN, Collins AJ, Hemodial Int 2007 11 1 62 71 17257358 (Pubitemid 46128682)
18. The phosphate binder equivalent dose. Daugirdas JT, Finn WF, Emmett M, Chertow GM, Semin Dial 2011 24 1 41 49 10.1111/j.1525-139X.2011.00849.x 21338393
19. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003 42 4 Suppl 3 1 S201 14520607
20. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Cunningham J, Locatelli F, Rodriguez M, Clin J Am Soc Nephrol 2011 6 4 913 921 10.2215/CJN.06040710 21454719
21. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB, N Engl J Med 2000 342 20 1478 1483 10.1056/NEJM200005183422003 10816185 (Pubitemid 30318271)
22. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Block GA, Hulbert-Shearon TE, Levin NW, Port FK, Am J Kidney Dis 1998 31 4 607 617 10.1053/ajkd.1998.v31.pm9531176 9531176